当归四逆汤联合依巴斯汀治疗慢性荨麻疹临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R758.24

基金项目:


Clinical Study on Danggui Sini Decoction Combined with Ebastine for Chronic Urticaria
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察当归四逆汤联合依巴斯汀治疗慢性荨麻疹疗效。方法:选择2021年3月—2023年 1 月东阳市中医院收治的82例慢性荨麻疹患者,按随机数字表法分为治疗组及对照组各41例。对照组采用依 巴斯汀治疗,治疗组采用依巴斯汀联合当归四逆汤治疗。比较2组临床疗效及不良反应发生率,比较2组治疗 前后荨麻疹活动评分(UAS)、血清免疫指标[免疫球蛋白E(IgE)、干扰素-γ(IFN-γ)、白细胞介素-4(IL-4)]、 趋化因子[单核细胞趋化蛋白-1(MCP-1)、正常T细胞表达和分泌因子(RANTES)] 水平的变化。结果:治 疗组临床疗效总有效率为97.56%(40/41),对照组临床疗效总有效率为80.49%(33/41),2组比较,差异有统 计学意义(P<0.05)。治疗后,2组UAS评分均较治疗前下降(P<0.05),治疗组UAS评分低于对照组(P< 0.05)。治疗后,2 组血清IgE、IL-4 水平均较治疗前下降(P<0.05),IFN-γ 水平均较治疗前升高(P< 0.05);治疗组IgE、IL-4水平均低于对照组(P<0.05),IFN-γ 水平高于对照组(P<0.05)。治疗后,2组 MCP-1、RANTES水平均较治疗前下降(P<0.05),治疗组MCP-1、RANTES水平均低于对照组(P<0.05)。 治疗组不良反应发生率为14.63% (6/41),对照组不良反应发生率为21.95% (9/41),2组不良反应发生率比 较,差异无统计学意义(P>0.05)。结论:当归四逆汤联合依巴斯汀治疗慢性荨麻疹疗效较好,可有效缓解临 床症状,调节免疫功能,安全性好。

    Abstract:

    Abstract: Objective: To observe the curative effect of Danggui Sini Decoction combined with Ebastine on chronic urticaria. Methods: A total of 82 cases of patients with chronic urticaria admitted to Dongyang Traditional Chinese Medicine Hospital from March 2021 to January 2023 were divided into the treatment group and the control group according to the random number table method, with 41 cases in each group. The control group was treated with Ebastine,and the treatment group was treated with Danggui Sini Decoction combined with Ebastine. Clinical effects and the incidence of adverse reactions were compared between the two groups. Changes in Urticaria Activity Score (UAS), serum immune markers [immunoglobulin E (IgE),interferon-γ (IFN-γ),interleukin-4 (IL-4)],and chemotactic factors [monocyte chemoattractant protein-1 (MCP-1), regulated upon activation normal T cell expressed and secreted (RANTES)] before and after treatment were compared between the two groups. Results: The total effective rate of clinical effect was 97.56% (40/41) in the treatment group and 80.49% (33/41) in the control group,with a significant difference between the two groups (P<0.05). After treatment,UAS scores in the two groups were decreased when compared with those before treatment (P<0.05), with the treatment group showing lower UAS score than the control group (P<0.05). The levels of IgE and IL-4 in serum in the two groups were decreased when compared with those before treatment (P<0.05),and IFN-γ levels in the two groups were increased when compared with those before treatment (P<0.05). After treatment,the levels of IgE and IL-4 in serum in the treatment group were lower than those in the control group (P<0.05),and IFN-γ level was higher than that in the control group (P<0.05). After treatment, the levels of MCP-1 and RANTES in the two groups were increased when compared with those before treatment (P< 0.05), with the treatment group showing greater reductions (P<0.05). The incidence of adverse reactions was 14.63% (6/41) in the treatment group and 21.95% (9/41) in the control group,with no significant difference between the two groups (P>0.05). Conclusion:Danggui Sini Decoction combined with Ebastine has a good curative effect in treating chronic urticaria, which can significantly alleviate clinical symptoms and modulate immune function, with good safety.

    参考文献
    相似文献
    引证文献
引用本文

楼丽红,吴晖.当归四逆汤联合依巴斯汀治疗慢性荨麻疹临床研究[J].新中医,2025,57(1):1-5

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-01-14
  • 出版日期:
文章二维码